Prothena traded at $31.61 this Wednesday August 17th, decreasing $0.51 or 1.59 percent since the previous trading session. Looking back, over the last four weeks, Prothena lost 5.37 percent. Over the last 12 months, its price fell by 45.82 percent. Looking ahead, we forecast Prothena to be priced at 30.92 by the end of this quarter and at 27.41 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
31.61
Daily Change
-1.59%
Yearly
-45.82%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Acadia Pharmaceuticals 17.06 0.10 0.59% 2.03%
Agios Pharmaceuticals 26.22 -1.19 -4.34% -37.94%
Akebia Therapeutics 0.41 -0.01 -2.57% -83.29%
ALKERMES 25.61 -0.84 -3.18% -13.36%
Alnylam Pharmaceuticals 223.13 -5.02 -2.20% 12.96%
Amgen 250.58 -2.57 -1.02% 10.47%
Biogen 217.58 -2.06 -0.94% -36.36%
Bluebird Bio 6.78 0.20 3.04% -62.52%
BioMarin Pharmaceutical 94.84 -0.19 -0.20% 25.55%
Exelixis 19.31 -0.20 -1.03% 5.75%
Intercept Pharmaceuticals 18.73 0.66 3.65% 31.72%
Incyte Corp 73.86 -1.10 -1.47% -0.91%
Ionis Pharmaceuticals 43.88 -0.44 -0.99% 15.38%
Intra Cellular Therapies 51.50 -2.31 -4.29% 77.22%
MacroGenics 4.49 -0.02 -0.44% -79.61%
Neurocrine Biosciences 104.94 -1.17 -1.10% 14.31%
Nektar Therapeutics 4.72 0.04 0.85% -65.09%
Prothena 31.61 -0.51 -1.59% -45.82%
Ultragenyx Pharmaceutical 47.25 -2.06 -4.18% -42.35%
Regeneron Pharmaceuticals 636.34 -12.36 -1.91% -2.94%
Seattle Genetics 170.79 0.27 0.16% 7.57%
Vertex Pharmaceuticals 299.23 -3.77 -1.24% 53.42%
Immunic Inc. 5.02 -0.07 -1.38% -47.27%
Xoma 17.85 -0.15 -0.83% -32.92%

Indexes Price Day Year
USND 12938 -164.43 -1.25% -10.93%
US2000 1987 -33.22 -1.64% -7.94%

Prothena
Prothena Corporation PLC is a late-stage clinical company. The Company is engaged in the protein dysregulation and a pipeline of therapeutics for devastating neurodegenerative and rare peripheral amyloid diseases. It is advancing a pipeline of therapeutic candidates around neurological dysfunction and the biology of misfolded proteins. The Company's clinical pipeline of antibody-based product candidates targets a range of indications, including Birtamimab for the treatment of amyloid light-chain (AL) amyloidosis; prasinezumab for the treatment of Parkinson’s disease and other related synucleinopathies; and PRX004, for the treatment of Transthyretin amyloidosis (ATTR). The Company's pipeline also includes late-preclinical-stage programs targeting proteins implicated in neurological diseases including tau and amyloid beta (Aß) for the treatment of Alzheimer’s disease and other neurodegenerative disorders, and TDP-43 for the treatment of amyotrophic lateral sclerosis.